Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery (CARVASAXe)
Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery: A Phase III Multicenter Randomized Controlled Study
Sponsor: Air Liquide Santé International
A PHASE3 clinical study on Coronary Arteries Disease Risk and Elevated Cardiac Risk, this trial is completed. The trial is conducted by Air Liquide Santé International and has accumulated 10 data snapshots since 2010. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
May 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Air Liquide Santé International
- Eurofins Biomnis
- Inferential
- Monitoring Force Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bordeaux, France , Caen, France , Clermont-Ferrand, France , Créteil, France , Dijon, France , Lille, France , Marseille, France , Paris, France , Poitiers, France , Rennes, France and 1 more location